Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107087 | 1.00 | CA2 (0.51) | CA2RAB9AGAAPRKAB2PRKAG1 | |
| SCHEMBL1107090 | 1.00 | CA2 (0.51) | CA2RAB9AGAAPRKAB2PRKAG1 | |
| SCHEMBL29444746 | 0.93 | CA2 (0.58) | CA2RAB9AGAALMNATSHR | |
| SCHEMBL29481813 | 0.93 | CA2 (0.58) | CA2RAB9AGAALMNATSHR | |
| SCHEMBL6984007 | 0.93 | CA2 (0.58) | CA2RAB9AGAALMNATSHR | |
| SCHEMBL6984001 | 0.93 | CA2 (0.58) | CA2RAB9AGAALMNATSHR | |
| SCHEMBL9116625 | 0.83 | CA2 (0.55) | CA2RAB9AGAALMNA | |
| SCHEMBL8596072 | 0.83 | CA2 (0.51) | CA2RAB9AGAALMNA | |
| SCHEMBL28720094 | 0.81 | FFAR1 (0.48) | CA2RAB9APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL11222928 | 0.81 | CA2 (0.49) | CA2RAB9AGAALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-RE45174-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-RE45174-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8524752-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-8524752-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-RE43833-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| WO-2005054215-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
| EP-0565732-B1 | BENZODIOXANE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-01-14 | — | — | EP | disclosed |
| US-5480905-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0565732-A1 | BENZODIOXANE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4579845-A | Antihypertensive cyanoguanidines | BOUCHARA S.A. (FR) | 1986-04-01 | — | — | US | disclosed |
| US-4539413-A | Preparation of 3-amino-1-[(1,4-benzodioxan)-2-yl-methoxy]-2-propanols | PIERRE FABRE S.A. (FR) | 1985-09-03 | — | — | US | disclosed |
| US-4456614-A | HYPOTENSIVE, AND ANTIARRHYTHMIA AGENT | PIERRE FABRE S.A. (FR) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | CA2 3655/4885RAB9A 1862/4885GAA 1429/4885 |
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | TLR4, IRF3, IL4 | CA2 3349/4885RAB9A 4170/4885GAA 2065/4885 |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | TLR4, IL4, IRF3 | CA2 3385/4885RAB9A 4261/4885GAA 1814/4885 |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | CA2 3385/4885RAB9A 4261/4885GAA 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.